Opko Health (OPK) : Rk Asset Management reduced its stake in Opko Health by 1.41% during the most recent quarter end. The investment management company now holds a total of 922,617 shares of Opko Health which is valued at $9,180,039 after selling 13,205 shares in Opko Health , the firm said in a disclosure report filed with the SEC on Jul 14, 2016.Opko Health makes up approximately 8.05% of Rk Asset Management’s portfolio.
Other Hedge Funds, Including , Eqis Capital Management reduced its stake in OPK by selling 3,828 shares or 16.62% in the most recent quarter. The Hedge Fund company now holds 19,207 shares of OPK which is valued at $192,838. Opko Health makes up approx 0.01% of Eqis Capital Management’s portfolio.Davenport Co boosted its stake in OPK in the latest quarter, The investment management firm added 39,000 additional shares and now holds a total of 76,000 shares of Opko Health which is valued at $730,360. Opko Health makes up approx 0.01% of Davenport Co’s portfolio.Fisher Asset Management reduced its stake in OPK by selling 41 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 37,826 shares of OPK which is valued at $363,508. Cutler Group Lp sold out all of its stake in OPK during the most recent quarter. The investment firm sold 3,382 shares of OPK which is valued $32,501.
Opko Health opened for trading at $10 and hit $10.08 on the upside on Monday, eventually ending the session at $10.04, with a gain of 0.90% or 0.09 points. The heightened volatility saw the trading volume jump to 23,26,783 shares. Company has a market cap of $5,496 M.
On the company’s financial health, Opko Health reported $-0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.03. The company had revenue of $291.00 million for the quarter, compared to analysts expectations of $266.30 million. The company’s revenue was up 866.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.26 EPS.
Many Wall Street Analysts have commented on Opko Health. Company shares were Reiterated by Standpoint Research on Jun 21, 2016 to “Buy”, Firm has raised the Price Target to $ 18 from a previous price target of $16 .Standpoint Research Initiated Opko Health on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $16.
OPKO Health Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose treat and prevent various conditions including point-of-care tests laboratory developed tests (LDTs) molecular diagnostics tests and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile Spain Mexico Israel Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.